Daily Briefing
Wednesday, February 11, 2026
The Vibe
Big Pharma is betting massive dollars on AI drug discovery while the FDA flexes new enforcement muscles. Takeda's $1.7B deal with Iambic Therapeutics shows how seriously pharma giants are taking AI platforms, while new FDA Commissioner Makary signals a crackdown on copycat drugs flooding the market [1][2]. The message is clear: AI innovation gets funded, regulatory shortcuts get hammered.
Research
•RAMA machine learning model predicts mortality risk in NICU patients with acute kidney injury, targeting one of the highest-risk pediatric populations [3]
•AI models using uterine activity patterns show promise for preterm birth prediction, potentially enabling earlier interventions [4]
•Natural language processing successfully deciphers gynecologic cytopathology reports for patient portal use, making complex pathology accessible to patients [5]
•Machine learning identifies four endothelial biomarkers (ANXA2, DBN1, ZNF385D, IL6ST) linking atherosclerosis progression to immune dysfunction [6]
Clinical Practice & Ops
•Bristol Myers partners with Evinova's AI-native clinical development platform across its global portfolio to cut trial costs and boost efficiency [7]
•Algorithm-driven wearable robots help elderly patients in Singapore's active aging centers maintain mobility while reducing fall risk and physiotherapist dependence [8]
•Infinitus launches Agentic AI Member Services Suite to personalize health plan communications and extend call center capacity [9]
Industry & Products
•Takeda inks $1.7B multiyear AI drug discovery deal with Iambic Therapeutics, leveraging the startup's full AI platform suite [1]
•University of Hong Kong develops AI-powered chatbot to train healthcare professionals in end-of-life communications at scale [10]
Policy & Regulatory
•FDA Commissioner Makary pledges swift action against companies mass-marketing "illegal copycat drugs" following Hims' Wegovy pill controversy [2]
One to Watch
Track how Bristol Myers' AI-native clinical trial partnership performs — if it delivers meaningful cost reductions and faster timelines, expect every major pharma to follow suit within 18 months.